In recent days, the news of the “new crown drug” fenugreek has aroused heated discussions, and it has also set off a wave of hype in the domestic stock market. As a result, the stock prices of many companies have risen sharply and even have a continuous daily limit. According to the Economic Information Daily, on May 16, due to the market enthusiasm triggered by the concept of fenugreek, Bio Valley soared by 29.97% in a single day, and many stocks such as North China Pharmaceutical, Fangsheng Pharmaceutical, Buchang Pharmaceutical, Qianjin Pharmaceutical and other stocks rose by the daily limit. . On May 17, some listed pharmaceutical companies continued to rise. As of the close of the day, Fangsheng Pharmaceutical closed up 6.86%, Buchang Pharmaceutical closed up 0.13%, and Bio Valley closed up 3.26%. The concept of fernin immediately aroused the attention of the capital market. Investors have gone to the interactive platform to ask listed companies whether they are involved in the fenugreek business. As of May 17, there have been 240 investor questions and answers searched on the Shenzhen Stock Exchange’s interactive platform with Qianjin vine as the keyword. Judging from the content of the responses, some listed companies responded to the production and sales of fenugreek. On May 16, Rhine Biotech stated on the interactive platform that the company’s products and processes do not currently cover the extraction of phyllostachys, but the company has extraction technology reserves for similar products. If there is a lot of demand in the market for fenugreek in the future.
[related_posts_by_tax taxonomies=”post_tag”]
The post The concept of “new crown medicine” fenugreek sparked speculation, and many listed companies announced clarification appeared first on Gamingsym.